A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Summary

Rationale: ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the majority of the target population. Purpose: The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA).

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications